

Company Contact**Brian Norton, CEO**

IR@wellgisticshealth.com

Investor Relations Contact**Scott Powell, President**

Skyline Corporate

Communications Group, LLC

info@skylineccg.com

+1.646.893.5835

Addressing a Broken System

Patients Face Rising Costs & Terrible Choices

15%**Rising Prescription Costs Per Year**

Patients are faced with rising medication costs – **10-15% -avg drug increase per year**

Source: CMS, AHA, Drug Channels

95%**Lack of Access Due to Monopolies**

95% of access to and pricing of U.S. Drugs are controlled by the Six Largest PBMs/Payers

Source: FTC, Market Watch

1 in 3**Adults Skip Prescribed Meds Due to High Costs**

Insurers' lack of coverage force **a third of patients to skip prescribed medications.**

Source: KFF: Kaiser Family Foundation / CAP: Center for American Progress

 **PHARMACIES**

Face pressure from major wholesalers and PBMs, who control drug pricing and often keep manufacturer rebates, increasing costs and shrinking pharmacy profits.

 **DRUG MANUFACTURERS**

Are stuck in PBMs' costly rebate programs, as well as regulatory mandates, compliance penalties, and delayed payments—with limited visibility into patient outcomes.

 **EMPLOYERS / HEALTHCARE PAYORS**

Trapped by PBMs — Face annual price increases which they cannot understand, & which impacts the quality of coverage they provide to their members.

 **HEALTHCARE PROVIDERS**

Operate blind—with limited visibility into drug costs, coverage, or fulfillment status, causing treatment delays and patient non-adherence.

The Wellgistics Health Solution

OUR THREE-PART ECOSYSTEM

A 50-state NABP-accredited wholesale distributor with 3PL and cold-chain capabilities that supplies over 6,500 pharmacies — covering one-third of U.S. independents—at 35–50% savings. Equipped with a dynamic sales team powered by data science, we are driving results for our manufacturer partners.



The middleware technology connects patients, employer groups, providers, pharmacies, payors, and pharma partners to streamline prescriptions, boost adherence, and enhance outcomes. The tech powers an end-to-end, patient-centered pharmacy service through a national fulfillment and clinical services network.



A direct-to-patient pharmacy serving 49 states nationwide for pharmaceutical manufacturers and TPA partners with complete customization of formulary options. It also operates as a central dispensing hub with in-house fulfillment, a call center, and dedicated customer support.

Wellgistics Health operates a fully integrated healthcare ecosystem that **connects drug manufacturers directly to pharmacies, patients, employers, and healthcare providers.**



Key Differentiators



OWNING THE FULL STACK

We own the full stack: wholesale, digital pharmacy, hub services, tech platform, and analytics



PHYSICAL & DIGITAL RAILS

We integrate physical infrastructure with an end-to-end AI powered tech stack



ELIMINATING MIDDLEMEN

We eliminate middlemen by delivering prompt, transparent, and rebate-free pricing



INDEPENDENT PHARMACY FOCUS

Our hub activates independent pharmacies, bringing care closer to home

Revenue Sources



Prescription Fulfillment Fees

via our wholesale and pharmacy operations



SaaS Platform Fees

from pharma, providers, pharmacies, and employers



Hub Services Fees

for benefits management, prior authorizations, and patient support from drug manufacturer



White-Label & DTP Program Fees

from patients via our wholly owned pharmacy



Subscription Fees

from patients and pharmacies



AI Analytics Fees

from drug manufacturers and employer groups

Future Growth Initiatives

Expand our vertically integrated pharmacy & distribution network

Accelerate direct-to-patient programs to deliver lower-cost, higher-access prescriptions

Deploy AI-powered technologies like HubRx AI and Einstein Rx at national scale

Grow employer carve-out solutions to increase prescription benefits transparency & affordability

Drive strategic partnerships with drug manufacturers, employer groups, & health organizations

Pursue strategic acquisitions that expand WGRX suite of core prescription logistics verticals

Operational Highlights



6,500+

Total Pharmacies engaged



200+

Manufacturers to date



12,500+

Total Products/NDC's



631

Pharmacies added in Q1 & Q2



\$18.65M

2025 Q1 + Q2 Pro Forma Revenue



2

Full Stack Tech Platforms:
Einstein Rx + HubRx Ai

Legal Disclaimer: This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect current views of the Company with respect to, among other things, operations and financial performance. Forward-looking statements may be identified by the use of words such as "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek," "foreseeable" and similar terms and phrases in this presentation. Forward-looking statements contained in this document are based on the management's current expectations and are subject to changes in circumstances and other risks and uncertainties. The Company cannot assure you that future developments affecting the Company will be those that the Company has anticipated. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond the control of the Company. Any forward-looking statement made by the Company in this document speaks only as of the date of this document. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions the Company may make. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.